AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04132505
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01446003
Drug: MK-8457
RxNorm normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 x 10-mg capsule BID for 10 days
Trial: NCT00966251
Drug: CT-011
RxNorm normalized name: CT-011
DrugBank: CT-011 (DB05916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-011
Trial: NCT02632916
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous denosumab 1.0mg/kg at baseline, 6 months, 12 months and 18 months
Trial: NCT00490555
Drug: Dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dutasteride 0.5 mg orally
Trial: NCT00490555
Drug: Depo-Medroxyprogesterone (DMPA)
RxNorm normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg DMPA injection on Day 0 IM (into the muscle)
Trial: NCT01815840
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vismodegib 150 mg hard gelatin capsule orally once daily
Trial: NCT02504580
Drug: Bupivacaine HCI (Marcaine)
RxNorm normalized name: bupivacaine Injection [Marcaine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCI (Marcaine) by injection.
Trial: NCT00334984
Drug: glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02435927
Drug: ASLAN001 + mFolfox6 (5-FU, leucovorin)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ASLAN001 in combination with 5-FU and leucovorin
Trial: NCT01055314
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01055314
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01055314
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01055314
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01055314
Drug: Vincristine Sulfate Liposome
RxNorm normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02112929
Drug: Hyperpolarized xenon
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
Trial: NCT01197885
Drug: IMAB362
RxNorm normalized name: immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimer
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less
Trial: NCT00444574
Drug: Methylphenidate Transdermal System
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
Trial: NCT00444574
Drug: Concerta
RxNorm normalized name: Concerta
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
Trial: NCT02914665
Drug: elamipretide
RxNorm normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg elamipretide administered intravenously once daily for 7 consecutive days
Trial: NCT01289743
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept 25 mg subcutaneously twice a week
Trial: NCT01230034
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pill, 5 and 10 mg/day, od, 24 weeks
Trial: NCT01230034
Drug: Imidapril
RxNorm normalized name: imidapril
DrugBank: Imidapril (DB11783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill, 10 and 20 mg/day, od, 24 weeks
Trial: NCT02496299
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
Trial: NCT04474600
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The induction and maintenance of anesthesia was performed by total intravenous anesthesia using propofol. In both groups, remifentanil is continuously infused throughout the surgery.
Trial: NCT04474600
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The induction and maintenance of anesthesia was performed by inhalation anesthesia using desflurane. In both groups, remifentanil is continuously infused throughout the surgery.
Trial: NCT03788291
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg by mouth twice a day starting on day 8 of cycle 1
Trial: NCT03788291
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.
Trial: NCT02496299
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
Trial: NCT00665561
Drug: Maraviroc along with an optimized background antiretroviral drug regimen
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc prescribed per approved local label.
Trial: NCT00665561
Drug: Optimized background antiretroviral drug regimen without maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
Trial: NCT00813488
Drug: Fentanyl Buccal Tablet
RxNorm normalized name: fentanyl Buccal Tablet
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician.
Trial: NCT00771524
Drug: Ceftobiprole
RxNorm normalized name: Ceftobiprole
DrugBank: Ceftobiprole (DB04918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
Trial: NCT00117260
Drug: Seasonale (levonorgestrel and ethinyl estradiol)
RxNorm normalized name: estradiol / ethinyl estradiol / levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00813488
Drug: Immediate release oxycodone
RxNorm normalized name: oxycodone Extended Release Oral Tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules).
Trial: NCT00604721
Drug: selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01630941
Drug: denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
Trial: NCT01858740
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01858740
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT01858740
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00258479
Drug: ModafinilNicotine Replacement Therapy
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
Trial: NCT00258479
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Modafinil Intervention Description above.
Trial: NCT03406338
Drug: Collagenase Clostridium Histolyticum
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
Trial: NCT04217785
Drug: Genteal lubricant gel
RxNorm normalized name: hypromellose Ophthalmic Gel [GenTeal]
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genteal lubricant gel (2 drops per day, for 8 weeks)
Trial: NCT00561574
Drug: Esmirtazapine
RxNorm normalized name: Esmirtazapine
DrugBank: Esmirtazapine (DB06678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet daily
Trial: NCT02704481
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg oral mifepristone
Trial: NCT02704481
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800mcg buccal misoprostol
Trial: NCT02704481
Drug: Placebo mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo pill of 200mg mifepristone
Trial: NCT02704481
Drug: Placebo misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo pills of 800mcg misoprostol
Trial: NCT03971357
Drug: Netarsudil
RxNorm normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: netarsudil opthalmic solution 0.02%
Trial: NCT00189605
Drug: Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of steroid solution into the lumbar level
Trial: NCT03927144
Drug: Oral Prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOC Oral Tablet/Capsule
Trial: NCT03747679
Drug: 200 Mg capsules of bosutinib in Water solution
RxNorm normalized name: bosutinib Oral Capsule
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg (4X50) Capsules in water
Trial: NCT00254475
Drug: valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01113229
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two misoprostol tablets taken orally (400µg)
Trial: NCT03747679
Drug: Bosutinib Mannitol
RxNorm normalized name: Bosutinib
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib mannitol solution
Trial: NCT03747679
Drug: bosutinib in mannitol low sweet
RxNorm normalized name: Bosutinib
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bosutinib in mannitol solution low sweet
Trial: NCT03747679
Drug: bosutinib in mannitol high sweet
RxNorm normalized name: Bosutinib
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bosutinib in mannitol high sweet
Trial: NCT03747679
Drug: bosutinib taste low flavour
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bosutinib solution low flavour
Trial: NCT03747679
Drug: bosutinib high flavour
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bosutinib solution high flavour
Trial: NCT03747679
Drug: bosutinib capsules in applesauce
RxNorm normalized name: bosutinib Oral Capsule
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib capsules in applesauce
Trial: NCT03747679
Drug: Bosutinib capsules in yogurt
RxNorm normalized name: bosutinib Oral Capsule
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bosutinib capsules in yogurt
Trial: NCT03747679
Drug: bosutinib capsules in water
RxNorm normalized name: bosutinib Oral Capsule
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: sham comparator, bosutinb in water retest
Trial: NCT03747679
Drug: Bosutinib capsules in low sweet
RxNorm normalized name: bosutinib Oral Capsule
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bosutinib capsules in low sweet
Trial: NCT03747679
Drug: bosutinib capsules high sweet
RxNorm normalized name: bosutinib Oral Capsule
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib capsules high sweet
Trial: NCT03747679
Drug: bosutinib capsules low flavour
RxNorm normalized name: bosutinib Oral Capsule
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib capsules low flavour
Trial: NCT03747679
Drug: bosutinib capsules high flavour
RxNorm normalized name: bosutinib Oral Capsule
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bosutinib capsules in high flavour
Trial: NCT03829722
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.
Trial: NCT03829722
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV once per week during radiation therapy (AUC=1).
Trial: NCT03829722
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV once per week during radiation therapy (30mg/m\^2)
Trial: NCT00927758
Drug: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fluticasone propionate/salmeterol diskus
Trial: NCT01608594
Drug: administration of ipilimumab 3mg/kg + HDI
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks.
Trial: NCT00001407
Drug: Interferon Gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00649090
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg oral tablet once daily for a maximum of 3 years
Trial: NCT04027751
Drug: Tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators administrated intravenously Tropisetron 5mg before anesthesia induction
Trial: NCT03442985
Drug: Palovarotene 2.5 mg
RxNorm normalized name: palovarotene 2.5 MG
DrugBank: Palovarotene (DB05467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
Trial: NCT03442985
Drug: Palovarotene 5.0 mg
DrugBank: Palovarotene (DB05467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
Trial: NCT02720536
Drug: Deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
Trial: NCT02837835
Drug: ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/kg of body weight followed by 60 mg/kg/day
Trial: NCT04374318
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: INTRATHECAL AND INTRAVENOUS
Trial: NCT02837835
Drug: ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/kg over 30 min every 8 h
Trial: NCT00836810
Drug: Timed Release Tablet Prednisone
RxNorm normalized name: prednisone Delayed Release Oral Tablet
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
Trial: NCT02216786
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet
Trial: NCT02216786
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Im injection
Trial: NCT02714725
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
Trial: NCT02714725
Drug: Placebo for Dexmedetomidine normal saline infusion
RxNorm normalized name: NS-2359
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During bypass, patients will receive normal saline infusion
Trial: NCT03953716
Drug: DING KUN DAN
RxNorm normalized name: Ding xiang
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
Trial: NCT03953716
Drug: Simulated drug of DING KUN DAN
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
Trial: NCT03953716
Drug: Marvelon
RxNorm normalized name: isopropyl alcohol
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marvelon 1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle
Trial: NCT03897335
Drug: Aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.
Trial: NCT00880217
Drug: Atomoxetine 80 mg/d
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
Trial: NCT00880217
Drug: OROS methylphenidate HCl 54 mg/d
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days